Tumor Lysis Syndrome Management

Definition and Classification

• Tumor lysis syndrome (TLS) is classified into laboratory TLS (LTLS) and clinical TLS (CTLS), with laboratory TLS defined by the presence of two or more abnormal serum values within three days before or seven days after initiation of anticancer therapy, according to the American Society of Clinical Oncology 1
• Clinical TLS requires laboratory TLS plus one or more clinical complications such as renal insufficiency, cardiac arrhythmias, or seizures, as defined by the European Society for Medical Oncology 2

Pathophysiology

• TLS occurs when tumor cells undergo rapid lysis, releasing intracellular contents including nucleic acids, proteins, phosphorus, and potassium into the bloodstream, leading to hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia, as described by the National Comprehensive Cancer Network 3
• Released nucleic acids are catabolized to hypoxanthine, then xanthine, and finally to uric acid by xanthine oxidase, resulting in uric acid precipitation in renal tubules and potential renal insufficiency or failure, according to the American College of Physicians 4

Risk Factors

• Pre-existing elevated uric acid levels, renal dysfunction, advanced age, dehydration, hyponatremia, and obstructive uropathy are host-related factors that increase the risk of TLS, as identified by the European Society for Medical Oncology 2
• High-grade hematologic malignancies with rapid proliferation rates, bulky disease with large tumor burden, extensive bone marrow involvement, high tumor sensitivity to chemotherapy, and elevated LDH levels are disease-related factors that increase the risk of TLS, according to the American Society of Hematology 1

Prevention and Management

• High-risk patients should receive hydration and rasburicase to prevent TLS, as recommended by the European Society for Medical Oncology 5
• Intermediate-risk patients should receive hydration plus either allopurinol or rasburicase, while low-risk patients should receive hydration and oral allopurinol, according to the National Comprehensive Cancer Network 5
• Aggressive hydration should be started 48 hours before tumor-specific therapy when possible, with a goal of maintaining urine output ≥100 mL/hour in adults, as recommended by the American Society of Clinical Oncology 6

Specific Interventions

• Allopurinol blocks xanthine oxidase activity, preventing conversion of hypoxanthine and xanthine to uric acid, with a dosage of 300 mg orally once daily, as described by the American College of Physicians 3
• Rasburicase is a recombinant urate-oxidase enzyme that converts existing uric acid to allantoin, with a dosage of 0.20 mg/kg/day, infused over 30 minutes for 3-5 days, according to the European Society for Medical Oncology 5

Monitoring and Indications for Dialysis

• High-risk patients should be monitored every 12 hours for the first three days, then every 24 hours, with parameters including vital signs, serum uric acid, electrolytes, and renal function, as recommended by the National Comprehensive Cancer Network 6
• Indications for dialysis include severe oliguria or anuria, persistent hyperkalemia, hyperphosphatemia with symptomatic hypocalcemia, hyperuricemia not responding to rasburicase, and severe volume overload, according to the American Society of Nephrology 6

Tumor Lysis Syndrome Risk Stratification

Malignancy-Specific Risks

• B-cell acute lymphoblastic leukemia (B-ALL) patients show a 26.4% rate of TLS development, representing one of the highest-risk malignancies for TLS, according to the Journal of Clinical Oncology 7
• Burkitt's lymphoma and B-ALL represent the absolute highest-risk malignancies for TLS, with acute lymphoproliferative disorders and high proliferative rates defining the upper limit of TLS risk, as stated by Haematologica 8
• AML with WBC > 100 × 10⁹/L represents the highest-risk scenario among the given choices, with white blood cell count > 50,000-100,000/mm³ being a major predictor of TLS development in acute leukemias, according to Haematologica 8
• Diffuse Large B-Cell Lymphoma (DLBCL) carries TLS risk, particularly with bulky disease, but the overall TLS rate in NHL is approximately 6.1%, with only 6% experiencing clinically significant symptoms requiring specific therapy, as reported by the Journal of Clinical Oncology 7
• Chronic Lymphocytic Leukemia (CLL) carries the lowest risk among hematologic malignancies, with TLS suspected in only 0.42% of patients and clinical or laboratory features in just 0.33% of patients, according to the Journal of Clinical Oncology 7

Key Risk Factors and Management

• Tumor burden indicators that predict TLS in AML with hyperleukocytosis include WBC count > 100 × 10⁹/L, elevated LDH levels, pre-existing renal impairment, and elevated baseline uric acid, as stated by Haematologica 8
• For AML patients with WBC > 100 × 10⁹/L, aggressive prophylaxis with hydration and rasburicase should be initiated immediately, and consideration of leukapheresis prior to chemotherapy may be necessary, according to Haematologica 9
• Delaying chemotherapy without addressing TLS risk first can result in a high mortality rate, with 83% mortality for clinical TLS in AML vs 24% in those without TLS, as reported by the Journal of Clinical Oncology 7

Tumor Lysis Syndrome Management

Diagnostic Criteria

• Hyperuricemia is defined as uric acid >8 mg/dL in adults (>8 mg/dL in children) 10, 11, 12
• Renal failure is defined as serum creatinine ≥1.5 times upper normal limit or creatinine clearance <60 mL/min 13
• Cardiac arrhythmias can range from intervention not indicated to life-threatening arrhythmias with CHF, hypotension, syncope, or shock 14, 13
• Seizures can occur, ranging from brief generalized seizures to status epilepticus 14, 13

Risk Stratification

• High-risk patients have significantly higher mortality rates (83% vs 24% in those without TLS) 10, 11, 12, 15
• Hyperuricemia (>8 mg/dL in children, >10 mg/dL in adults) is a high-risk factor 15
• High-grade lymphomas, particularly T-cell lymphoblastic NHL, are high-risk diseases 10, 11, 12
• Acute lymphoblastic leukemia in adults and advanced T-cell ALL in children are high-risk diseases 10, 11, 12
• Bulky disease (especially bulky SCLC or massive liver metastases) is a high-risk factor 10, 11, 12
• Metastatic germ cell tumors (gonadal or extragonadal) are high-risk diseases 10, 11, 12
• Elevated serum LDH >2 times upper normal limit is a high-risk factor 10, 11, 12

Pre-Treatment Evaluation

• Creatinine clearance or estimated GFR should be evaluated before starting anticancer therapy 10, 11, 12
• Serum LDH levels should be evaluated before starting anticancer therapy 10, 11, 12
• Renal ultrasound should be performed in all patients undergoing chemotherapy 10, 11, 12
• Baseline uric acid, potassium, phosphate, and calcium levels should be evaluated before starting anticancer therapy 12

Prophylaxis Strategy

• Low-risk patients should receive oral allopurinol 100 mg/m² three times daily (maximum 800 mg/day) and vigorous hydration (≥2 L/m²/day) 10, 11, 12, 15
• High-risk patients should receive rasburicase 0.20 mg/kg/day IV over 30 minutes plus aggressive hydration in an inpatient setting 10, 11, 12, 15
• Rasburicase should not be administered concurrently with allopurinol to avoid xanthine accumulation and lack of substrate for rasburicase 10, 11, 12

Monitoring Protocol

• High-risk patients should be monitored every 12 hours for the first 3 days, then every 24 hours for LDH, uric acid, sodium, potassium, creatinine, BUN, phosphorus, and calcium 12
• Patients with established TLS should be monitored every 6 hours for the first 24 hours, then daily for vital signs, uric acid, electrolytes, creatinine, and BUN 12, 16
• Continuous ECG monitoring should be performed for hyperkalemic patients 16

Treatment of Established TLS

• All patients with clinical TLS or laboratory TLS with worsening parameters should receive hydration through central venous access and rasburicase immediately 16
• Aggressive IV hydration should be administered at 3 L/m²/day to maintain urine output ≥100 mL/hour in adults 16
• Loop diuretics may be required to maintain urine output, except in obstructive uropathy or hypovolemia 16
• Rasburicase should be administered at 0.20 mg/kg/day IV over 30 minutes for 3-5 days 16

Indications for Dialysis

• Renal replacement therapy should be initiated for severe oliguria or anuria unresponsive to medical management, persistent hyperkalemia despite medical therapy, hyperphosphatemia with symptomatic hypocalcemia, hyperuricemia not responding to rasburicase, severe volume overload, or symptomatic uremia 16
• Hemodialysis effectively removes uric acid (clearance 70-100 mL/min) and phosphate, with plasma uric acid falling approximately 50% with each 6-hour treatment 16

Guideline Recommendations for Diagnosis, Grading, and Management of Tumor Lysis Syndrome

Renal Assessment and Monitoring

• The expert panel advises estimating glomerular filtration rate (eGFR) using MDRD or Cockcroft‑Gault equations rather than relying on serum creatinine alone, because creatinine is a delayed and muscle‑mass‑dependent marker of acute kidney injury in patients at risk for tumor lysis syndrome. 17
• In the same context, the panel emphasizes that serum creatinine alone should not be used to diagnose renal dysfunction in TLS; calculated eGFR provides a more accurate assessment of kidney injury. 18

Cardiac Complication Grading

• Cardiac arrhythmias in TLS are classified from Grade I (no intervention required) to Grade IV (life‑threatening arrhythmias associated with heart failure, hypotension, syncope, or shock). This grading guides the intensity of monitoring and therapeutic response. 19

Neurological Complication Grading

• Seizure severity in TLS is graded from Grade II (brief, generalized seizures well‑controlled with anticonvulsants) to Grade IV (status epilepticus or intractable epilepsy), informing the need for urgent neurologic intervention. 19

Overall Clinical Grading System for TLS

• Clinical TLS severity is assigned a grade (I–IV) based on the highest‑grade organ complication observed (renal, cardiac, or neurologic). This unified grading system standardizes risk stratification and treatment decisions. 17

Grade Definitions (Applicable to all organ systems)

All grade definitions are derived from the 2008 Haematologica consensus. 19

Essential Diagnostic Workup

• Baseline evaluation for patients undergoing cytoreductive therapy should include measurement of uric acid, potassium, phosphate, calcium, creatinine, BUN, and LDH, with renal function quantified by creatinine clearance or eGFR calculated via MDRD or Cockcroft‑Gault formulas. 17

Critical Pitfalls to Avoid

• Do not depend solely on serum creatinine for renal assessment in TLS; always calculate eGFR to detect early kidney injury. 17
• Recognize that in solid‑tumor TLS, mortality approaches 35%, underscoring the need for prompt recognition and prophylaxis. 19